# Boomray

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boomray

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.boomray.com
- Total disclosed funding: $44M
- Latest round: Series A (Sep 1, 2022)
- Investors on record: 7

## About

Based in Beijing, China, and established in 2020, Boomray is a biopharmaceutical company that focuses on the R&D, production, and clinical application of targeted radionuclide therapy for tumors. Boomray is a joint venture, co-established by Wuxi AppTec Group, and Peking University Sunan Research Institute.  And it has an R&D centre in Beijing.  

Boomray provides targeted radionuclide drugs that diagnose and treat neck tumors, brain tumors, pancreatic tumors, rectal tumors, and prostate tumors. Radiopharmaceuticals consist of radioactive atoms and target molecules destroying cancer cells.

## Funding rounds

- Series A, Sep 1, 2022, $44M — Hong Shan, Puhua Capital, Riverhead Capital, Tsing Song Capital, Chengdu Tianfu Sanjiang Asset Management, Lccap, Shenzhen Jinsheng Equity Investment Management

## Investors

- Hong Shan — Series A
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Chengdu Tianfu Sanjiang Asset Management — Series A
- Lccap — Series A
- Shenzhen Jinsheng Equity Investment Management — Series A